Plasma Proteomic Analysis May Identify New Markers for Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 3, 2010, Pages 867-876

  Cai, Xu Wei ^a,c   Ao, Xiaoping ^a   Davis, Mary ^a   Fu, Xiao Long ^c   Lawrence, Theodore S ^a  

^a Spring)   (United States)

^b Spring)   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

biomarker; Non small cell lung cancer; proteomics; radiation induced lung toxicity

Indexed keywords

NON SMALL CELL LUNG CANCER; PROTEOMICS; RADIATION-INDUCED; RADIATION-INDUCED LUNG TOXICITY;

BIOLOGICAL ORGANS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR BIOLOGY; PLASMAS; RADIATION; RADIOTHERAPY; TOXICITY;

PROTEINS;

ANGIOTENSINOGEN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR H; CYTOKERATIN 5; VITRONECTIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NANOANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; RADIATION INJURY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSINOGEN; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPLEMENT C3; COMPLEMENT C4B-BINDING PROTEIN; FEMALE; HUMANS; KERATINS, TYPE II; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NANOTECHNOLOGY; PROTEINS; PROTEOMICS; RADIATION INJURIES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; VITRONECTIN;

EID: 77952618694     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.01.038     Document Type: Article

References (53)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Tyldesley S., Boyd C., Schulze K., et al. Estimating the need for radiotherapy for lung cancer: An evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 49 (2001) 973-985
3. Kong F.M., Ten Haken R.K., Schipper M.J., et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 324-333
4. Rosenzweig K.E., Fox J.L., Yorke E., et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 103 (2005) 2118-2127
5. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 318-328
6. Anscher M.S., Kong F.M., Marks L.B., et al. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 37 (1997) 253-258
7. Fu X.L., Huang H., Bentel G., et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 50 (2001) 899-908
8. Kong F.M., Ten Haken R., Eisbruch A., et al. Non-small cell lung cancer therapy-related pulmonary toxicity: An update on radiation pneumonitis and fibrosis. Semin Oncol 32 (2005) S42-54
9. Sung H.J., and Cho J.Y. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 41 (2008) 615-625
10. Latterich M., Abramovitz M., and Leyland-Jones B. Proteomics: New technologies and clinical applications. Eur J Cancer 44 (2008) 2737-2741
11. Ao X., Lubman D.M., Davis M.A., et al. Comparative proteomic analysis of radiation-induced changes in mouse lung: Fibrosis-sensitive and -resistant strains. Radiat Res 169 (2008) 417-425
12. Kong F.M., Hayman J.A., Griffith K.A., et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65 (2006) 1075-1086
13. Schlautman J.D., Rozek W., Stetler R., et al. Multidimensional protein fractionation using ProteomeLab PF 2Dtrade mark for profiling amyotrophic lateral sclerosis immunity: A preliminary report. Proteome Sci 6 (2008) 26
14. Gygi S.P., Rist B., Gerber S.A., et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17 (1999) 994-999
15. Patterson S.D., and Aebersold R.H. Proteomics: The first decade and beyond. Nat Genet 33 Suppl (2003) 311-323
16. Liu Y., He J., Ji S., et al. Comparative studies of early liver dysfunction in senescence-accelerated mouse using mitochondrial proteomics approaches. Mol Cell Proteomics 7 (2008) 1737-1747
17. Ong S.E., Blagoev B., Kratchmarova I., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1 (2002) 376-386
18. Nesvizhskii A.I., Keller A., Kolker E., et al. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75 (2003) 4646-4658
19. Lubman D.M., Kachman M.T., Wang H., et al. Two-dimensional liquid separations-mass mapping of proteins from human cancer cell lysates. J Chromatogr B Anal Technol Biomed Life Sci 782 (2002) 183-196
20. Hamler R.L., Zhu K., Buchanan N.S., et al. A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics 4 (2004) 562-577
21. Buchanan N.S., Hamler R.L., Leopold P.E., et al. Mass mapping of cancer cell lysates using two-dimensional liquid separations, electrospray-time of flight-mass spectrometry, and automated data processing. Electrophoresis 26 (2005) 248-256
22. Lee H.J., Kang M.J., Lee E.Y., et al. Application of a peptide-based PF2D platform for quantitative proteomics in disease biomarker discovery. Proteomics 8 (2008) 3371-3381
23. Denison C., Rudner A.D., Gerber S.A., et al. A proteomic strategy for gaining insights into protein sumoylation in yeast. Mol Cell Proteomics 4 (2005) 246-254
24. Venable J.D., Wohlschlegel J., McClatchy D.B., et al. Relative quantification of stable isotope labeled peptides using a linear ion trap-Orbitrap hybrid mass spectrometer. Anal Chem 79 (2007) 3056-3064
25. Feng S., Yang N., Pennathur S., et al. Enrichment of glycoproteins using nanoscale chelating concanavalin A monolithic capillary chromatography. Anal Chem 81 (2009) 3776-3783
26. Chou J., Choudhary P.K., and Goodman S.R. Protein profiling of sickle cell versus control RBC core membrane skeletons by ICAT technology and tandem mass spectrometry. Cell Mol Biol Lett 11 (2006) 326-337
27. Duan X., Chen X., Yang Y., et al. Precolumn derivatization of cysteine residues for quantitative analysis of five major cytochrome P450 isoenzymes by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 21 (2007) 3234-3244
28. Koomen J.M., Haura E.B., Bepler G., et al. Proteomic contributions to personalized cancer care. Mol Cell Proteomics 7 (2008) 1780-1794
29. Conrad D.H., Goyette J., and Thomas P.S. Proteomics as a method for early detection of cancer: A review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 23 (2008) 78-84
30. Patz E.F., Campa M.J., Gottlin E.B., et al. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25 (2007) 5578-5583
31. Malard V., Prat O., Darrouzet E., et al. Proteomic analysis of the response of human lung cells to uranium. Proteomics 5 (2005) 4568-4580
32. Menard C., Johann D., Lowenthal M., et al. Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 66 (2006) 1844-1850
33. Xu N.Y., Zhang S.P., Nie J.H., et al. Radon-induced proteomic profile of lung tissue in rats. J Toxicol Envir Health 71 (2008) 361-366
34. Chung L.P., Bentley D.R., and Reid K.B. Molecular cloning and characterization of the cDNA coding for C4b-binding protein, a regulatory protein of the classical pathway of the human complement system. Biochem J 230 (1985) 133-141
35. Blom A.M., Villoutreix B.O., and Dahlback B. Functions of human complement inhibitor C4b-binding protein in relation to its structure. Arch Immunol Ther Exp (Warsz) 52 (2004) 83-95
36. Okroj M., Jenkins H.T., Herbert A.P., et al. Structural basis and functional effects of the interaction between complement inhibitor C4b-binding protein and DNA. Mol Immunol 46 (2008) 62-69
37. Janssen B.J., Huizinga E.G., Raaijmakers H.C., et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437 (2005) 505-511
38. de Bruijn M.H., and Fey G.H. Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci U S A 82 (1985) 708-712
39. Sahu A., and Lambris J.D. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 180 (2001) 35-48
40. Jenne D., and Stanley K.K. Nucleotide sequence and organization of the human S-protein gene: Repeating peptide motifs in the "pexin" family and a model for their evolution. Biochemistry 26 (1987) 6735-6742
41. Felding-Habermann B., and Cheresh D.A. Vitronectin and its receptors. Curr Opin Cell Biol 5 (1993) 864-868
42. Kamikubo Y., Okumura Y., and Loskutoff D.J. Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin. J Biol Chem 277 (2002) 27109-27119
43. Zhou A., Huntington J.A., Pannu N.S., et al. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10 (2003) 541-544
44. Calvano S.E., Xiao W., Richards D.R., et al. A network-based analysis of systemic inflammation in humans. Nature 437 (2005) 1032-1037
45. Uriarte S.M., Powell D.W., Luerman G.C., et al. Comparison of proteins expressed on secretory vesicle membranes and plasma membranes of human neutrophils. J Immunol 180 (2008) 5575-5581
46. Zhao L., Wang L., Ji W., et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: A combined analysis from Beijing and Michigan. Int J Radiat Oncol Biol Phys 74 (2009) 1385-1390
47. Birgel M., Gottschling-Zeller H., Rohrig K., et al. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 20 (2000) 1682-1687
48. Rossi M., Sharkey A.M., Vigano P., et al. Identification of genes regulated by interleukin-1beta in human endometrial stromal cells. Reproduction 130 (2005) 721-729
49. Schoppet M., Chavakis T., Al-Fakhri N., et al. Molecular interactions and functional interference between vitronectin and transforming growth factor-beta. Lab Invest 82 (2002) 37-46
50. Parker T., Upton Z., and Leavesley D. Vitronectin modulates human mesenchymal stem cell response to insulin-like growth factor-I and transforming growth factor beta 1 in a serum-free environment. Tissue Eng Part A 15 (2009) 1415-1426
51. Kobayashi H., Suzuki M., Tanaka Y., et al. A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade. J Biol Chem 278 (2003) 7790-7799
52. Samarakoon R., and Higgins P.J. Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Haemost 100 (2008) 976-983
53. Zhao L., Sheldon K., Chen M., et al. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer 59 (2008) 232-239